DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: valsartan

Summary for Generic Name: valsartan

Tradenames:2
Patents:2
Applicants:2
NDAs:3
Drug Master File Entries: see list27
Suppliers: see list11
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: valsartan

Tentative approvals for VALSARTAN

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL80MG
<disabled><disabled>TABLET; ORAL160MG
<disabled><disabled>TABLET; ORAL320MG

Clinical Trials for: valsartan

Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension
Status: Recruiting Condition: Hypertension

To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone
Status: Completed Condition: Hypertension; High Blood Pressure

Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
Status: Completed Condition: Essential Hypertension

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Status: Recruiting Condition: Hypertrophic Cardiomyopathy

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
Status: Completed Condition: Hypertension

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Status: Completed Condition: Diabetes Mellitus, Type 2

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ohm Labs Inc
VALSARTAN
valsartan
TABLET;ORAL077492Jun 26, 2014RXNo<disabled>PATENT CHALLENGE
Novartis
DIOVAN
valsartan
TABLET;ORAL021283Jul 18, 2001RXYes6,294,197*PED<disabled>Y
Novartis
DIOVAN
valsartan
TABLET;ORAL021283Jul 18, 2001RXYes5,972,990*PED<disabled>Y
Novartis
DIOVAN
valsartan
TABLET;ORAL021283Jul 18, 2001RXNo6,294,197*PED<disabled>Y
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc